Here are the DEF 14A proxy statements from Processa Pharmaceuticals, Inc. (PCSA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PCSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCSA filings page.
Processa Pharmaceuticals, Inc. is asking stockholders to authorize a reverse split of its issued and outstanding common stock at a ratio from one new share for every three shares to one for every nine shares, with the Board choosing the final ratio. The vote is scheduled for November 30, 2026. If approved, the Board may implement the split at a time it determines necessary or advisable, but no later than one year after the meeting. Stockholders will also vote on a proposal to adjourn the meeting if needed to continue soliciting votes.
Processa says the split is intended to help meet Nasdaq’s $4.00-per-share minimum market-price criterion before a separate meeting on conversion of Series A Preferred Stock. The split would not reduce authorized common shares. As of October 21, 2026, Processa had 2,798,241 common shares outstanding and 306,574.202 Series A Preferred shares outstanding; conversion remains subject to separate stockholder approval and beneficial-ownership limitations. Processa completed its merger with Vidya on July 28, 2026, and issued preferred shares to private-placement investors on July 30 for approximately $200 million in gross proceeds.
Processa Pharmaceuticals is holding its 2026 annual shareholder meeting on July 30, 2026 in Kennesaw, Georgia. Shareholders will vote on electing six directors, increasing the 2019 Omnibus Incentive Plan share reserve by 200,000 shares, ratifying Cherry Bekaert as auditor for 2026, and approving 2025 executive pay on an advisory basis.
Shareholders of record as of June 1, 2026, when 2,768,032 common shares were outstanding, are entitled to vote in person or by proxy, including online and telephone options.